Trends in receipt of adjuvant chemotherapy and impact on survival in resected biliary tract cancers

Abstract

Background: Resection remains the cornerstone of curative-intent treatment for biliary tract cancer (BTC), however, recent randomized data support a survival benefit with the addition of adjuvant chemotherapy (AC) in these patients. Herein, we aimed to characterize trends and disparities in the utilization of AC and subsequent outcomes in gallbladder cancer and cholangiocarcinoma (CCA).